Search

Patients with axial spondyloarthritis (axSpA) who receive immunosuppressive therapy are at risk of infection due to impaired immune function and immunosuppressive medication. Vaccination plays a crucial role in preventing infections in this population. However, vaccination rates and factors influencing vaccination uptake in axSpA patients still need to be adequately studied. This study was designed to determine the vaccination rates of vaccines covered by health insurance in this particular group in Turkey and attitudes towards vaccines and infections. This survey included 199 patients with axSpA who visited our outpatient clinic in June, July, and August 2023 and received biologic and targeted synthetic disease-modifying antirheumatic drugs. The mean age of the participants was 43.7 ± 0.7 years, and the majority were male (66.3%). The majority of the patients were vaccinated against COVID-19 (85.4%), followed by hepatitis B (41.2%), influenza (20.1%), and pneumococcal pneumonia (10.5%). While awareness of COVID-19 vaccination was widespread (100%), knowledge of other vaccines was lower (hepatitis B 80.9%, influenza 70.3%, pneumococcal 60.3%, respectively). Educational interventions targeting patients and healthcare professionals are needed to improve vaccination rates in this population. Our findings emphasize the need for strategies to increase vaccination rates in axSpA patients receiving immunosuppressive therapy. Removing barriers to vaccination and raising awareness of the importance of vaccination are critical to optimizing vaccination practices in this vulnerable population. [ABSTRACT FROM AUTHOR]

Objectives: The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods: We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25–30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results: There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3–33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05). Conclusions: This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients. [ABSTRACT FROM AUTHOR]

Background: Information and education are recommended for patients with inflammatory arthritis including spondyloarthritis (SpA). However, there is no Turkish instrument available to measure the knowledge level of patients with SpA. The study aimed to translate the Spondyloarthritis Knowledge Questionnaire (SPAKE) into Turkish and investigate its validity and reliability. Methods: This methodological study was conducted between February 2023 and August 2023 in patients with SpA. Data were collected using the "Patient Characteristics Form" and the "Turkish version of SPAKE (SPAKE-T)." Language, content, item analysis, known-group technique, test--retest, and internal consistency were used to evaluate validity and reliability. Results: A total of 226 SpA patients participated in the study. The validity and reliability analysis of SPAKE-T showed the following results: (a) content validity index at item level between 0.86 and 1.00, (b) significant correlation between the total score of the questionnaire and its sub domains between 0.18 and 0.81 (P < .05), (c) item difficulty between 0.11 and 0.91, (d) item discrimination index between 0.26 and 0.81, (e) within the known group validity, significantly lower knowledge scores in patient groups with low education level, disease duration less than 10 years, and patients who did not receive education about their disease (P < .05), (f ) Cronbach alpha value was 0.80, and (g) test--retest reliability was 0.81. Conclusion: This study indicates that the SPAKE-T, which has satisfactory psychometric properties, can be easily used to assess the overall knowledge level of patients with SpA about disease self-management. [ABSTRACT FROM AUTHOR]

Objectives: This study aimed to evaluate the hepatitis B (HBV) and C (HCV) frequency and clinical characteristics among patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who receive biological treatments. Patients and methods: The observational study was conducted with patients from the TReasure database, a web-based prospective observational registry collecting data from 17 centers across Türkiye, between December 2017 and June 2021. From this database, 3,147 RA patients (2,502 males, 645 females; median age 56 years; range, 44 to 64 years) and 6,071 SpA patients (2,709 males, 3,362 females; median age 43 years; range, 36 to 52 years) were analyzed in terms of viral hepatitis, patient characteristics, and treatments used. Results: The screening rate for HBV was 97% in RA and 94.2% in SpA patients. Hepatitis B surface antigen (HBsAg) positivity rates were 2.6% and 2%, hepatitis B surface antibody positivity rates were 32.3% and 34%, hepatitis B core antibody positivity rates were 20.3% and 12.5%, HBV DNA (deoxyribonucleic acid) positivity rates were 3.5% and 12.5%, and antibody against HCV positivity rates were 0.8% and 0.3% in RA and SpA patients, respectively. The HBsAg-positive patients were older and had more comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, rheumatoid factor (RF) positivity was more common in HBsAg-positive cases. The most frequently prescribed biologic disease-modifying antirheumatic drugs were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group and adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. Hepatitis B reactivation was observed in one RA patient during treatment, who received rituximab and prophylaxis with tenofovir. Conclusion: The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Uludag University Medical Faculty / Uludağ Üniversitesi Tıp Fakültesi Dergisi is the property of Journal of Uludag University Medical Faculty and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Uludag University Medical Faculty / Uludağ Üniversitesi Tıp Fakültesi Dergisi is the property of Journal of Uludag University Medical Faculty and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The aetiology may be complex in patients presenting with fever and rash. The differential diagnosis may include coronavirus disease 2019 (COVID-19) infection, an adverse effect of the COVID-19 vaccine, infection, and vasculitis. We reported a patient who presented with fever and vasculitic rash, which we hypothesized was an adverse vaccine effect. A 35-year-old male patient presented to the emergency department reporting headache, fever, rash, weakness, and myalgia. The first dose of the mRNA vaccine, COVID-19, had been administered five days before his presentation. A nasopharyngeal severe acute respiratory syndrome coronavirus twochallenge test was negative. Antinuclear antibody, antineutrophil cytoplasmic antibody, rheumatoid factor, and cryoglobulin were negative. No hypocomplementemia was detected. Skin biopsy was predominantly lymphocytic, with a vasculitic reaction with a few neutrophils. The Rickettsia conorii immunoglobulin M test examined using enzyme-linked immunosorbent assay (ELISA) was positive. COVID-19 should be excluded in patients with fever, rash, and headache. Symptoms that occur after vaccination may indicate adverse reactions. Even though we are in the pandemic phase, rickettsiosis should not be forgotten. [ABSTRACT FROM AUTHOR]